All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treatment sequencing for anemic myelofibrosis

with Jean-Jacques Kiladjian & Angela Fleischman

Monday, February 26, 2024 | 16:30 CET

This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2022-01-28T15:50:32.000Z

MOMENTUM study of momelotinib for myelofibrosis meets primary endpoint

Jan 28, 2022
Share:

Bookmark this article

On January 25, 2022, it was announced that the phase III, pivotal MOMENTUM (NCT04173494) study, evaluating momelotinib for the treatment of patients with symptomatic myelofibrosis (MF), achieved both its primary and major secondary endpoints; momelotinib has been associated with statistically significant improvements in symptoms, spleen size, and anemia.

Momelotinib

Momelotinib is an orally available inhibitor of Janus kinase 1 and 2 (JAK1/2) and activin A receptor type I/activin receptor-like kinase-2 (ALK-2). The agent is currently being evaluated across a number of clinical trials for the treatment of patients with MF who have received prior treatment with a U.S. Food and Drug administration (FDA)-approved JAK inhibitor.

MOMENTUM

MOMENTUM is a phase III, double-blind, randomized study investigating momelotinib versus danazol in patients aged ≥18 years with MF who meet the following eligibility criteria:

  • Symptomatic with a Total Symptom Score (TSS) of ≥10.
  • Anemic with hemoglobin of <10 g/dL at baseline.
  • Prior treatment with a FDA-approved JAK inhibitor.

Across 21 countries, 195 patients were enrolled and randomized 2:1 to momelotinib (n = 130) and danazol (n = 65) treatment arms. Patients receiving danazol were able to transfer to momelotinib after 24 weeks of treatment, or earlier in the instance of splenic progression.

The study used the following endpoints to establish the value of momelotinib in MF:

  • Primary endpoint: ≥50% reduction of TSS at the end of Week 24 compared to baseline.
  • Secondary endpoints: transfusion independence for ≥12 weeks with maintained hemoglobin at ≥8 g/dL, and splenic response rate of ≥35% volume reduction at Week 24.

Results

Topline data from the MOMENTUM study demonstrate the encouraging efficacy and safety profiles of momelotinib versus danazol for patients with MF (Figure 1).

Figure 1. A Efficacy and B safety outcomes observed in patients enrolled in the MOMENTUM study*

AEs, adverse events; SRR, splenic response rate; TEAEs, treatment-emergent adverse events; TI, transfusion independence; TSS, Total Symptom Score.
*Data from BusinessWire1

Findings from the MOMENTUM study suggest that momelotinib represents a promising treatment approach to MF with anemia, or patients with MF who may progress to symptomatic anemia.

  1. BusinessWire. Sierra oncology announces momelotinib achieved statistically significant benefit on symptoms, anemia and splenic size in the pivotal MOMENTUM study for myelofibrosis. https://www.businesswire.com/news/home/20220125005390/en/Sierra-Oncology-Announces-Momelotinib-Achieved-Statistically-Significant-Benefit-on-Symptoms-Anemia-and-Splenic-Size-in-the-Pivotal-MOMENTUM-Study-for-Myelofibrosis. Published Jan 25, 2022. Accessed Jan 26, 2022.

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox